« Back to Our Team list

Daniel Alexander Laheru, M.D.

Daniel Alexander Laheru, M.D.
Co-Director, Skip Viragh Center for Pancreas Cancer
Ian T. MacMillan Professorship in Clinical Pancreatic Cancer Research
Associate Professor of Oncology

Appointment Phone: 410.955.8964

Dr. Laheru currently serves as an Associate Professor of Oncology at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University School of Medicine. Dr. Laheru specializes in gastrointestinal oncology with a specific focus in pancreatic cancer. His clinical research interests are in developing and testing new therapies for the treatment of pancreatic cancer. He has developed a clinical trial program to optimize a vaccine approach using GM-CSF transfected pancreatic cell lines as a vaccine in two distinct patient populations. He has also incorporated correlative studies that should provide important information to better understand optimal vaccine boosting schedules as well as to identify antigens that can be predictive in-vitro markers for anti-tumor immune responses. Dr. Laheru is investigating mechanisms of chemotherapy resistance in pancreatic cancer and will be developing and testing new targets for therapy in patients with metastatic pancreas cancer.

Selected Publications

  • Villarroel, M.C.; Rajeshkumar, N.V.; Garrido-Laguna, I.; De Jesus-Acosta, A.; Jones, S.; Maitra, A.; Hruban, R.H.; Eshleman, J.R.; Klein, A.; Laheru, D.; Donehower, R.; Hidalgo, M. Personalizing Cancer Treatment in the Age of Global Genomic Analyses: PALB2 Gene Mutations and the Response to DNA Damaging Agents in Pancreatic Cancer. Mol Cancer Ther. 2011 Jan;10(1):3-8.

  • Lutz, E.; Yeo, C.J.; Lillemoe, K.D.; Biedrzycki, B.; Kobrin, B.; Herman, J.; Sugar, E.; Piantadosi, S.; Cameron, J.L.; Solt, S.; Onners, B.; Tartakovsky, I.; Choi, M.; Sharma, R.; Illei, P.B.; Hruban, R.H.; Abrams, R.A.; Le, D.; Jaffee, E.; Laheru, D. A Lethally Irradiated Allogeneic Granulocyte-Macrophage Colony Stimulating Factor-Secreting Tumor Vaccine for Pancreatic Adenocarcinoma: A Phase II Trial of Safety, Efficacy, and Immune Activation. Ann Surg. 2011 Jan 6;Epub 1/11/11.

  • Weekes, C.D.; Nallapareddy, S.; Rudek, M.A.; Norris-Kirby, A.; Laheru, D.; Jimeno, A.; Donehower, R.C.; Murphy, K.M.; Hidalgo, M.; Baker, S.D.; Messersmith, W.A. Thymidylate synthase (TYMS) enhancer region genotype-directed phase II trial of oral capecitabine for 2nd line treatment of advanced pancreatic cancer. Invest New Drugs. 2010 Mar 23.

  • Voong, K.R.; Davison, J.; Pawlik, T.M.; Uy, M.O.; Hsu, C.C.; Winter, J.; Hruban, R.H.; Laheru, D.; Rudra, S.; Swartz, M.J.; Nathan, H.; Edil, B.H.; Schulick, R.; Cameron, J.L.; Wolfgang, C.L.; Herman, J.M. Resected pancreatic adenosquamous carcinoma: clinicopathologic review and evaluation of adjuvant chemotherapy and radiation in 38 patients. Hum Pathol. 2010 Jan;41(1):113-122.

  • Swartz MJ, Hsu CC, Pawlik TM, Winter J, Hruban RH, Guler M, Schulick RD, Cameron JL, Laheru DA, Wolfgang CL, Herman JM: Adjuvant chemoradiotherapy after pancreatic resection for invasive carcinoma associated with intraductal papillary mucinous neoplasm of the pancreas . Int J Radiat Oncol Biol Phys. 2010 Mar 1;76(3):839-44. Epub 2009 Aug 3.PMID: 19647950